BishtRef
Articles Journals Publishers Authors Subjects Most Cited New Papers Year Stats Open Access
journal article Jun 01, 2005

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

K.A. Papp S. Tyring M. Lahfa J. Prinz C.E.M. Griffiths A.M. Nakanishi R. Zitnik P.C.M. van de Kerkhof
British Journal of Dermatology Vol. 152 No. 6 pp. 1304-1312 · Oxford University Press (OUP)
View at Publisher Save 10.1111/j.1365-2133.2005.06688.x
Topics

No keywords indexed for this article. Browse by subject →

References
16
[1]
Finlay AY Br J Dermatol (1995) 10.1111/j.1365-2133.1995.tb05019.x
[2]
Rapp SR J Am Acad Dermatol (1999) 10.1016/s0190-9622(99)70112-x
[3]
Krueger GG Arch Dermatol (2001)
[7]
Moreland LW Ann Intern Med (1999) 10.7326/0003-4819-130-6-199903160-00004
[14]
Fredriksson T Dermatologica (1978) 10.1159/000250839
[16]
Hochberg Y Biometrika (1988) 10.1093/biomet/75.4.800
Cited By
587
Biosimilar versus originator etanercept: a real-life clinical study

Domenico Giordano, Alessandro CAPALBO · 2022

Italian Journal of Dermatology and...
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation

Scott M. Whitlock, Clinton W. Enos · 2018

Journal of the American Academy of...
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

Jason E Hawkes, Bernice Y Yan · 2018

The Journal of Immunology
Tildrakizumab for the treatment of psoriasis

Rodney Sinclair, Vetrichevvel Thirthar Palanivelu · 2018

Expert Review of Clinical Immunolog...
Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis

Chris Cameron, Brian Hutton · 2018

Journal of Comparative Effectivenes...
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Kristian Reich, Kim A Papp · 2017

The Lancet
Old and New Biological Therapies for Psoriasis

Kirsten Rønholt, Lars Iversen · 2017

International Journal of Molecular...
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Christopher E M Griffiths, Kristian Reich · 2015

The Lancet
Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review

Aikaterini-Evaggelia Moustou, Athina Matekovits · 2009

Journal of the American Academy of...
Metrics
587
Citations
16
References
Details
Published
Jun 01, 2005
Vol/Issue
152(6)
Pages
1304-1312
License
View
Authors
K
K.A. Papp
S
S. Tyring
M
M. Lahfa
J
J. Prinz
C
C.E.M. Griffiths
A
A.M. Nakanishi
R
R. Zitnik
P
P.C.M. van de Kerkhof
Cite This Article
K.A. Papp, S. Tyring, M. Lahfa, et al. (2005). A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology, 152(6), 1304-1312. https://doi.org/10.1111/j.1365-2133.2005.06688.x
Related

You May Also Like

Classification of the cutaneous manifestations of COVID ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases

C. Galván Casas, A. Català · 2020

982 citations

Cellular and molecular mechanisms of repair in acute and chronic wound healing

P. Martin, R. Nunan · 2015

932 citations

Epidemiology of acne vulgaris

K. Bhate, H.C. Williams · 2013

606 citations

Minoxidil: mechanisms of action on hair growth

A.G. Messenger, J. Rundegren · 2004

522 citations

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

A. Wollenberg, A. Blauvelt · 2020

520 citations